NCT06731673

Heat Shock Protein 47 in Thrombosis

Heat Shock Protein 47: A Novel Biomarker of Thrombosis Risk

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 340 (estimated)
• Sponsor: University of Aarhus · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The goal of this observational study is to learn if the novel biomarker Heat shock protein 47 (HSP47) can be used as a prognostic marker for vascular disease in people with acute venous thromboembolism (VTE), myocardial infarction (AMI) or ischaemic stroke compared to healthy volunteers. The main questions it aims to answer are: 1. Are platelet levels of HSP47 higher in patients with acute VTE, AMI or stroke, compared to healthy volunteers. 2. Does platelet levels of HSP47 remain elevated in patients with acute thrombotic events compared to healthy volunteers at 3 and 12-months of follow-up. 3. Are platelet levels of HSP47 postively associated with platelet function and negatively associated with fibrinolytic capacity in patients with an acute thrombotic event. Participants with VTE, AMI or stroke will be giving a blood sample at diagnosis and again after 3 and 12 months of follow-up. Healthy volunteers will be giving a blood sample once.

Conditions

• Venous Thromboembolism (VTE)
• Acute Myocardial Infarction With ST Segment Elevation
• Stroke (in Patients With Atrial Fibrillation)

Timeline

• Start date: 2024-12-09
• Primary completion: 2027-08-31
• Completion: 2027-08-31
• First posted: 2024-12-12
• Last updated: 2025-08-21

Locations

2 sites across 2 countries: Denmark, Germany